Please login to the form below

Not currently logged in

Dr Keith Bragman joins Alacrita

He becomes a partner at the firm’s London office

Alacrita Dr Keith BragmanLife sciences consultancy Alacrita has appointed Dr Keith Bragman as a partner in its London office.

Dr Bragman brings a wealth of industry experience to the firm, having served on the Science and Technology Select Committee at the House of Commons, worked with the Bill and Melinda Gates Foundation and at the UK government's department for international development.

He has held a number of senior leadership positions at pharmaceutical companies, including serving as head of global development and research for UCB's Japanese business, vice president and senior partner for biotechnology at Quintiles, and European head of clinical oncology at Bristol-Myers Squibb.

Managing partner Anthony Walker said: “We are delighted to welcome Keith to our product development practice as we build a best-in-class consulting practice to help companies develop better therapeutics.

“Keith is an experienced executive with deep and broad knowledge of the drug development process and a sound understanding of the challenges faced by senior management.

“He joins a high calibre team of seasoned consultants and underlines our commitment to providing exceptionally high quality advice to the industry.”

30th June 2016

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
McCann Complete Medical

Complete Medical delivers world-class solutions in medical communications, regulatory services, healthcare multichannel excellence, and strategic consultancy. We bring together specialist...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...